MDM2 SNP309 polymorphism is associated with lung cancer risk in women: A meta-analysis using METAGEN

He,Wenwu; Long,Jianxiong; Xian,Lei; Pang,Feng; Su,Li; Wei,Shixiu; Wei,Bo; Hu,Yanling

doi:10.3892/etm.2012.640

MDM2 SNP309 polymorphism is associated with lung cancer risk in women: A meta-analysis using METAGEN

Authors:
- Wenwu He
- Jianxiong Long
- Lei Xian
- Feng Pang
- Li Su
- Shixiu Wei
- Bo Wei
- Yanling Hu
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, P.R. China , School of Public Health, Guangxi Medical University, Nanning, Guangxi, P.R. China, Fourth Grade of Clinical Medicine, Guangxi Medical University, Nanning, Guangxi, P.R. China, Medical Research Center, Guangxi Medical University, Nanning, Guangxi, P.R. China
Published online on: July 18, 2012 https://doi.org/10.3892/etm.2012.640
Pages: 569-576

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the most common diagnosed malignancy and the leading cause of cancer-related mortality worldwide. Murine double minute 2 (MDM2) SNP309 polymorphisms have been reported to influence the risk of lung cancer. However, the published studies together with four subsequent meta-analyses have yielded contradictory results. To examine this inconsistency, we conducted a meta-analysis of 6,696 lung cancer cases and 7,972 controls from eight published case-control studies using METAGEN. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated with STATA software and used to assess the strength of the association. In the overall analysis, a significant association between MDM2 SNP309 polymorphism and lung cancer risk was observed (OR, 1.143; 95% CI, 1.047-1.247). Moreover, stratified by ethnicity, a significant association was found in Asians (OR, 1.260; 95% CI, 1.111-1.429), but not in Europeans. Subgroup analysis of gender, histology and smoking status suggested that the MDM2 SNP309 genotype was associated with increased lung cancer risk in women (OR, 1.282; 95% CI, 1.062-1.548) and never smokers (OR, 1.328; 95% CI, 1.119‑1.575). No statistically significant association was observed in males and ever smoking population, and no association was found in subgroup analysis based on histology. In conclusion, the association between MDM2 SNP309 and lung cancer was statistically significant, particularly in Asians, women and never smoking population.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Chiang HC, Wang CY, Lee HL and Tsou TC: Metabolic effects of CYP2A6 and CYP2A13 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced gene mutation - a mammalian cell-based mutagenesis approach. Toxicol Appl Pharmacol. 253:145–152. 2011. View Article : Google Scholar : PubMed/NCBI
3	Spitz MR, Wei Q, Dong Q, Amos CI and Wu X: Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev. 12:689–698. 2003.PubMed/NCBI
4	Wang LE, Cheng L, Spitz MR and Wei Q: Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer. 42:1–8. 2003. View Article : Google Scholar : PubMed/NCBI
5	Vonlanthen S, Heighway J, Kappeler A, Altermatt HJ, Borner MM and Betticher DC: p21 is associated with cyclin D1, p16INK4a and pRb expression in resectable non-small cell lung cancer. Int J Oncol. 16:951–957. 2000.PubMed/NCBI
6	Brooks CL and Gu W: p53 ubiquitination: Mdm2 and beyond. Mol Cell. 21:307–315. 2006. View Article : Google Scholar : PubMed/NCBI
7	Alt JR, Bouska A, Fernandez MR, Cerny RL, Xiao H and Eischen CM: Mdm2 binds to Nbs1 at sites of DNA damage and regulates double strand break repair. J Biol Chem. 280:18771–18781. 2005. View Article : Google Scholar : PubMed/NCBI
8	Bouska A, Lushnikova T, Plaza S and Eischen CM: Mdm2 promotes genetic instability and transformation independent of p53. Mol Cell Biol. 28:4862–4874. 2008. View Article : Google Scholar : PubMed/NCBI
9	Li G, Zhai X, Zhang Z, Chamberlain RM, Spitz MR and Wei Q: MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis. 27:2028–2033. 2006. View Article : Google Scholar : PubMed/NCBI
10	Hu Z, Ma H, Lu D, et al: Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer. 118:1275–1278. 2006. View Article : Google Scholar : PubMed/NCBI
11	Pine SR, Mechanic LE, Bowman ED, et al: MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev. 15:1559–1561. 2006. View Article : Google Scholar : PubMed/NCBI
12	Ma H, Hu Z, Zhai X, et al: Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett. 240:261–267. 2006. View Article : Google Scholar : PubMed/NCBI
13	Onat OE, Tez M, Ozcelik T and Toruner GA: MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res. 26:3473–3475. 2006.PubMed/NCBI
14	Ohmiya N, Taguchi A, Mabuchi N, et al: MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol. 24:4434–4440. 2006. View Article : Google Scholar : PubMed/NCBI
15	Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, et al: The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet. 42:694–698. 2005.
16	Bond GL, Hu W, Bond EE, et al: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 119:591–602. 2004. View Article : Google Scholar : PubMed/NCBI
17	Park SH, Choi JE, Kim EJ, et al: MDM2 309T>G polymorphism and risk of lung cancer in a Korean population. Lung Cancer. 54:19–24. 2006.
18	Zhang X, Miao X, Guo Y, et al: Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat. 27:110–117. 2006. View Article : Google Scholar : PubMed/NCBI
19	Chua HW, Ng D, Choo S, et al: Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore. BMC Cancer. 10:882010. View Article : Google Scholar : PubMed/NCBI
20	Lind H, Zienolddiny S, Ekstrom PO, Skaug V and Haugen A: Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer. 119:718–721. 2006. View Article : Google Scholar : PubMed/NCBI
21	Liu G, Wheatley-Price P, Zhou W, et al: Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk. Int J Cancer. 122:915–918. 2008. View Article : Google Scholar : PubMed/NCBI
22	Mittelstrass K, Sauter W, Rosenberger A, et al: Early onset lung cancer, cigarette smoking and the SNP309 of the murine double minute-2 (MDM2) gene. BMC Cancer. 8:1132008. View Article : Google Scholar : PubMed/NCBI
23	Bai J, Dai J, Yu H, Shen H and Chen F: Cigarette smoking, MDM2 SNP309, gene–environment interactions, and lung cancer risk: a meta-analysis. J Toxicol Environ Health A. 72:677–682. 2009.
24	Gui XH, Qiu LX, Zhang HF, et al: MDM2 309 T/G polymorphism is associated with lung cancer risk among Asians. Eur J Cancer. 45:2023–2026. 2009. View Article : Google Scholar : PubMed/NCBI
25	Wan Y, Wu W, Yin Z, Guan P and Zhou B: MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis. BMC Cancer. 11:2082011. View Article : Google Scholar : PubMed/NCBI
26	Wo X, Han D, Sun H, et al: MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis. J Genet Genomics. 38:341–350. 2011.PubMed/NCBI
27	Bagos PG and Nikolopoulos GK: A method for meta-analysis of case-control genetic association studies using logistic regression. Stat Appl Genet Mol Biol. 6:Article 17. 2007.PubMed/NCBI
28	Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
29	Midgette AS, Wong JB, Beshansky JR, Porath A, Fleming C and Pauker SG: Cost-effectiveness of streptokinase for acute myocar-dial infarction: A combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. Med Decis Making. 14:108–117. 1994. View Article : Google Scholar : PubMed/NCBI
30	Higgins JP, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ. 327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
31	Rose L SM, Cardwell CR, Jouvet P, McAuley DF and Blackwood B: Automated versus non-automated weaning for reducing the duration of mechanical ventilation for critically ill adults and children. Cochrane Database Syst Rev. 7:CD0092352011. View Article : Google Scholar
32	Higgins JPT and Green S: Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0, updated March 2011. The Cochrane Collaboration. 2011.Available from https://www.cochrane-handbook.org.
33	Li H, Ha TC and Tai BC: XRCC1 gene polymorphisms and breast cancer risk in different populations: a meta-analysis. Breast. 18:183–191. 2009. View Article : Google Scholar : PubMed/NCBI
34	Begg CB and Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics. 50:1088–1101. 1994. View Article : Google Scholar : PubMed/NCBI
35	Heist RS, Zhou W, Chirieac LR, et al: MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J Clin Oncol. 25:2243–2247. 2007. View Article : Google Scholar : PubMed/NCBI
36	Han JY, Lee GK, Jang DH, Lee SY and Lee JS: Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer. 113:799–807. 2008. View Article : Google Scholar : PubMed/NCBI
37	Chien WP, Wong RH, Cheng YW, Chen CY and Lee H: Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors. Ann Surg Oncol. 17:1194–1202. 2010. View Article : Google Scholar : PubMed/NCBI
38	Dong J, Ren B, Hu Z, et al: MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese. Mol Carcinog. 50:433–438. 2011. View Article : Google Scholar : PubMed/NCBI
39	Jun HJ, Park SH, Lee WK, et al: Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer. Mol Carcinog. 46:100–105. 2007. View Article : Google Scholar : PubMed/NCBI
40	Wan JT, et al: Meta-analysis of association between SNP309 in MDM2 promoter and lung cancer susceptibility. Chin J Cancer Prev Treat. 5:655–658. 2008.(In Chinese).
41	Higgins JP: Commentary: Heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol. 37:1158–1160. 2008. View Article : Google Scholar : PubMed/NCBI
42	Groenwold RH, Rovers MM, Lubsen J and van der Heijden GJ: Subgroup effects despite homogeneous heterogeneity test results. BMC Med Res Methodol. 10:432010. View Article : Google Scholar : PubMed/NCBI